A small drafting mistake can have major consequences in patent law. That was the lesson from Enanta Pharmaceuticals, Inc. v. Pfizer Inc., where the Federal Circuit held in a precedential opinion that Enanta’s patent could not rely on the filing date of its earlier provisional application. Because the provisional application, as specifically written, did not clearly describe the version of the invention later claimed in the issued patent, Pfizer’s intervening public disclosure of nirmatrelvir—the active ingredient in Paxlovid—constituted prior art that anticipated and invalidated Enanta’s claims.
The issue turned on a single carbon atom! Enanta’s provisional application described a chemical substituent as having a C2-C12 alkyl group, meaning a chain of two to twelve carbon atoms. But the later-issued patent claimed a C1-C12 alkyl group. This was an attempt to cover a one-carbon chain. That one-carbon version was critical for Enanta because it would encompass Pfizer’s nirmatrelvir.